AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3036724
Drug: sequential intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential intermittent polychemotherapy (sq CT) after surgery
Trial: 3036724
Drug: standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard chemotherapy (CT) after surgery
Trial: 19515182
Drug: 3.9-5.0 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9-5.0 mmol/l FPG target
Trial: 19515182
Drug: 4.4-6.1 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4-6.1 mmol/l FPG target
Trial: 11231370
Drug: Furosemide 250
RxNorm normalized name: furosemide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 250 mg every day
Trial: 10095796
Drug: Quinapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20 mg once daily)
Trial: 2905110
Drug: Piribedil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (0.5 mg intravenously over 10 minutes)
Trial: 27063071
Drug: Selexipag 400
RxNorm normalized name: SELEXIPAG 400MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag 400 μg
Trial: 27063071
Drug: Warfarin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 20 mg
Trial: 23644932
Drug: Lutein (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (10 mg) + Zeaxanthin (2 mg)
Trial: 23644932
Drug: DHA (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (350 mg) + EPA (650 mg)
Trial: 18400776
Drug: Intravenous antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antivenom
Trial: 18400776
Drug: Intramuscular antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular antivenom
Trial: 15930213
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg, followed by 5 mg/kg after 24 and 48 hours)
Trial: 12540788
Drug: 5-isosorbide mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-isosorbide mononitrate (ISMN; 10 mg)
Trial: 8800885
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by consultant
Trial: 8800885
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by trainee
Trial: 1815520
Drug: Prajmalium bitartrate
RxNorm normalized name: prajmalium bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prajmalium bitartrate tablet (Neo‐Gilurytmal)
Trial: 1815520
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of prajmalium bitartrate
Trial: 26387037
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TA) - single dose of 20 mg/kg
Trial: 16136031
Drug: Negative cytological
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative cytological preparations with positive HPV test
Trial: 8729308
Drug: Esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.5 mg.kg‐1
Trial: 8729308
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg.kg‐1
Trial: 30659292
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment for 6 months (n=62)
Trial: 30659292
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=28)
Trial: 30659292
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment (n=62)
Trial: 29402680
Drug: No methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No methadone treatment
Trial: 25131184
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (T-gel) for 6 months
Trial: 25131184
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (T-gel)
Trial: 17461702
Drug: Acetaminophen 1
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 g twice/day
Trial: 17461702
Drug: Acetaminophen 4
RxNorm normalized name: acetaminophen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4 g/day
Trial: 17461702
Drug: Combined acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined acetaminophen groups
Trial: 15114096
Drug: Vasosol (VSL)
RxNorm normalized name: phenylephrine / sulfacetamide sodium Ophthalmic Solution [Vasosulf]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasosol (VSL) machine perfusion solution
Trial: 15114096
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (Belzer MPS)
Trial: 17257280
Drug: Diazoxide, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide, 100 mg at bedtime
Trial: 1377741
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment phase
Trial: 31466305
Drug: Maple products
RxNorm normalized name: coast maple pollen extract Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maple products (6% CHO solution)
Trial: 31466305
Drug: Commercial sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial sports drink (6% CHO solution)
Trial: 31466305
Drug: Glucose (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (control CHO solution)
Trial: 31466305
Drug: Water (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control solution)
Trial: 25619125
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) with lowest PAO quartiles
Trial: 20626355
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 4 mg at the end of surgery and 12 mg added to PCA (group O)
Trial: 20626355
Drug: Intravenous ramosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ramosetron 0.3 mg at the end of surgery and no antiemetics added to PCA (group R1)
Trial: 20626355
Drug: Intravenous ramosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ramosetron 0.3 mg at the end of surgery and 0.6 mg added to PCA (group R2)
Trial: 17717627
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g of mixed cruciferous vegetables
Trial: 17717627
Drug: 350 g
RxNorm normalized name: ALCOHOL 350 g in 500 mL TOPICAL GEL [C2V LINE CLEAR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 g of mixed cruciferous vegetables
Trial: 16310607
Drug: Subcutaneous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous unfractionated heparin for routine thromboprophylaxis
Trial: 16310607
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin for specific high-risk patients
Trial: 12037271
Drug: Act‐Hib in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Act‐Hib in combination with BE DTwP (Group A, n = 160)
Trial: 12037271
Drug: BE DTwP
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BE DTwP and Act‐Hib as separate injections (Group C, n = 58)
Trial: 9873862
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU of alpha interferon thrice weekly (TIW) for 3 months
Trial: 9873862
Drug: Individualized dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dose regimen tapering interferon dose from 3 or 6 MU by one-third every 2 months if transaminases were persistently normal
Trial: 9873862
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose regimen (3 or 6 MU thrice weekly)
Trial: 9873862
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (biochemical nonresponders followed for an additional 6 months)
Trial: 31357748
Drug: nal-IRI monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal-IRI monotherapy
Trial: 31578954
Drug: elvitegravir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily
Trial: 31578954
Drug: tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tenofovir disoproxil fumarate (300 mg)
Trial: 23698590
Drug: +45T>G SNP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +45T>G SNP, GG subjects
Trial: 19634823
Drug: Augmentation plate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation plate fixation with or without autogenous cancellous bone graft
Trial: 16702888
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/d or more (n = 120)
Trial: 16702888
Drug: Risperidone 3
RxNorm normalized name: risperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 3 mg/d or more (n = 115)
Trial: 8985298
Drug: Lamivudine 300
RxNorm normalized name: lamivudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 300 mg daily
Trial: 8107547
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (100 mg.d-1)
Trial: 27526120
Drug: MP4CO (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP4CO (15 mg/kg/dose to 172 mg/kg/dose, single IV doses; two cohorts received fractionated doses of 172 or 344 mg/kg)
Trial: 20537746
Drug: Vildagliptin 50mg
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 50mg twice-daily
Trial: 16149743
Drug: Formula fortified
RxNorm normalized name: S-M-A Iron Formula Fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula fortified with NT at 34 mg/L
Trial: 16149743
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula with an innate level of NT at 10 mg/L
Trial: 10565626
Drug: Isotretinoin treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin treatment for 30 days
Trial: 1651857
Drug: Clinical criteria
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical criteria (CC) and manual evaluation of TOF
Trial: 1651857
Drug: Clinical criteria
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical criteria (CC) only
Trial: 7034669
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and occupational therapy in the stroke unit
Trial: 7034669
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and occupational therapy in medical units
Trial: 31256761
Drug: Plan C
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plan C (standard rapid rehydration using Ringer's lactate 100 ml/kg over 3 hours, incorporating 0.9% saline boluses for children with shock)
Trial: 31256761
Drug: Slow rehydration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow rehydration (100 ml/kg Ringer's lactate over 8 hours without boluses)
Trial: 30095637
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide/salbutamol sulfate (COM)
Trial: 24821196
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine hydrochloride (50 mg)
Trial: 17667569
Drug: IgE for
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgE for morphine
Trial: 17667569
Drug: ROC analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROC analysis for morphine
Trial: 16401960
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy (13 fractions, 3.0 Gy per fraction, and 4 fractions at 4.5 Gy per fraction, total dose of 57 Gy)
Trial: 16401960
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (37 fractions, 2.0 Gy per fraction, total dose of 74 Gy)
Trial: 16401960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified treatment, but included in the study)
Trial: 10613619
Drug: 100‐mg enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100‐mg enteric‐coated diclofenac tablets
Trial: 10613619
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g acetaminophen plus 60 mg codeine
Trial: 10613619
Drug: 100‐mg enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen
Trial: 10613619
Drug: 100‐mg enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen plus 60 mg codeine
Trial: 7864704
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg BID for 7 days
Trial: 7864704
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg BID for 3 days
Trial: 7864704
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg BID for 3 days
Trial: 7864704
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg once daily for 3 days
Trial: 7864704
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg once daily for 5 days
Trial: 7864704
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg BID for 7 days
Trial: 9058224
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 0.25% bupivacaine
Trial: 26714202
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI treatment (escitalopram or sertraline)
Trial: 26714202
Drug: SNRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNRI treatment (venlafaxine)
Trial: 23650968
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) 200 μg/100 μl
Trial: 23650968
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 200 µg
Trial: 18256417
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii for five days in addition to oral rehydration solution (ORS)
Trial: 1336356
Drug: Type I,
RxNorm normalized name: Collagen Type I, Bovine
DrugBank: Bovine type I collagen (DB10771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type I, insulin‐dependent diabetic subjects with microalbuminuria
Trial: 1336356
Drug: Normoalbuminuric type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoalbuminuric type I, insulin‐dependent diabetic subjects
Trial: 2866786
Drug: Bucindolol 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucindolol 50, 100 and 200 mg
Trial: 2866786
Drug: Oxprenolol 40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 40, 80 and 160 mg
Trial: 16981899
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 15 min
Trial: 16981899
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 2 h
Trial: 14712987
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine oestrogen, 0.625 mg/day
Trial: 14712987
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol patches, 50 microg/day
Trial: 14712987
Drug: No hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormones
Trial: 10737822
Drug: Mandatory urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory urine drug screening
Trial: 8855811
Drug: Estradiol replacement
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol replacement therapy (micronized estradiol [Estrace TM], 2 mg orally each day)
Trial: 8855811
Drug: Estradiol replacement
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol replacement therapy (in subset with less than 3 months of amenorrhea)
Trial: 8855811
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (in subset with greater than 3 months of amenorrhea)
Trial: 6379570
Drug: Intravenous cefamandole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefamandole, 1.5 g before incision followed by 1.5 g every four hours up to the 24th postoperative hour
Trial: 6379570
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (control group K-)
Trial: 31045590
Drug: Curcumin (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (3000 mg/d)
Trial: 28626868
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg meperidine
Trial: 28626868
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of normal saline (Control)
Trial: 21242793
Drug: Enhanced cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cleaning of the near-patient environment (twice-daily for 2 months)
Trial: 18271889
Drug: Saffron 30
RxNorm normalized name: SAFFRON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron 30 mg/day (15 mg twice a day; morning and evening)
Trial: 17192685
Drug: Sanazole biweekly
RxNorm normalized name: Gynazole-1
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sanazole biweekly 1.25 g intravenous infusion 15 minutes before radiotherapy
Trial: 14578723
Drug: Restricted intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intravenous fluid regimen
Trial: 14578723
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous fluid regimen
Trial: 8969353
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5% lidocaine, 2.5% prilocaine) applied 1 hour before phlebotomy
Trial: 1472142
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder preparation (900 mg daily for 6 weeks)
Trial: 1472142
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder preparation
Trial: 26570994
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (omega-3) 3 g/day, taken 3 times a day for 90 days
Trial: 26570994
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil (placebo) 3 g/day, taken 3 times a day for 90 days
Trial: 23442582
Drug: Killed whole-virus
RxNorm normalized name: INFLUENZA A VIRUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole-virus HIV vaccine
Trial: 23442582
Drug: Therapeutic HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic HBV vaccine
Trial: 23442582
Drug: New tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tuberculosis vaccine candidate